Press Releases Marinus Pharmaceuticals, Inc.

Equities

MRNS

US56854Q2003

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-06 pm EDT			5-day change	1st Jan Change
1.48 ^USD	-1.99%		+5.71%	-86.38%

Apr. 17	Truist Adjusts Marinus Pharmaceuticals' PT to $10 From $25, Keeps Buy Rating	MT
Apr. 16	Baird Downgrades Marinus Pharmaceuticals to Neutral, Price Target at $2	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conference	May. 02	BU
Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024	May. 01	BU
Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results	Apr. 15	BU
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)	Apr. 05	BU
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus Post Grant Review	Mar. 28	AQ
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review	Mar. 27	BU
Marinus Pharmaceuticals: Q4 Earnings Snapshot	Mar. 05	AQ
Marinus Pharmaceuticals : Corporate Overview Slide Deck	Mar. 05	PU
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	Mar. 05	BU
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences	Feb. 21	BU
Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024	Feb. 20	BU
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)	Feb. 16	BU
Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2023 ZTALMY Net Product Revenue and Provides Business Update	Jan. 05	AQ
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)	Jan. 04	BU
Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2023 ZTALMY® Net Product Revenue and Provides Business Update	Jan. 04	BU
Marinus Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)	Dec. 08	AQ
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)	Dec. 07	BU
Marinus Pharmaceuticals : Corporate Overview Slide Deck	Nov. 27	PU
Marinus Pharmaceuticals Announces Seven Presentations at AES 2023, New Publication in Epilepsia and Results From the Second Generation Formulation MAD Study	Nov. 20	BU
Marinus Pharmaceuticals to Present at the 6th Annual Evercore ISI HealthCONx Conference	Nov. 14	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Marinus Pharmaceuticals, Inc.

Equities

MRNS

US56854Q2003

Press Releases

Filters